Zobrazeno 1 - 10
of 335
pro vyhledávání: '"MAO-B inhibitors"'
Autor:
Ali Irfan, Ameer Fawad Zahoor, Yassir Boulaamane, Sadia Javed, Huma Hameed, Amal Maurady, Muhammed Tilahun Muhammed, Sajjad Ahmad, Aamal A. Al-Mutairi, Irum Shahzadi, Sami A. Al-Hussain, Magdi E. A. Zaki
Publikováno v:
Frontiers in Chemistry, Vol 12 (2024)
Monoamine oxidase B (MAO-B) plays a pivotal role in the deamination process of monoamines, encompassing crucial neurotransmitters like dopamine and norepinephrine. The heightened interest in MAO-B inhibitors emerged after the revelation that this enz
Externí odkaz:
https://doaj.org/article/312cfb2526f9428a906bf9a1a766e73d
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 38, Iss 1 (2023)
Alzheimer’s disease (AD) is a progressive brain disease characterised by progressive memory loss and cognition impairment, ultimately leading to death. There are three FDA-approved acetylcholinesterase inhibitors (donepezil, rivastigmine, and galan
Externí odkaz:
https://doaj.org/article/80579e54291b4fdcad0b514c3e1209a9
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 38, Iss 1 (2023)
To discover novel multifunctional agents for the treatment of Parkinson’s disease, a series of 2-(4-(benzyloxy)-5-(hydroxyl) phenyl) benzothiazole derivatives was designed, synthesized and evaluated. The results revealed that representative compoun
Externí odkaz:
https://doaj.org/article/6865a0b7fce344078fd4ef62dabbc9db
Autor:
Ahmed H. E. Hassan, Hyeon Jeong Kim, Min Sung Gee, Jong-Hyun Park, Hye Rim Jeon, Cheol Jung Lee, Yeonwoo Choi, Suyeon Moon, Danbi Lee, Jong Kil Lee, Ki Duk Park, Yong Sup Lee
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 768-780 (2022)
Multifunctional molecules might offer better treatment of complex multifactorial neurological diseases. Monoaminergic pathways dysregulation and neuroinflammation are common convergence points in diverse neurodegenerative and neuropsychiatric disorde
Externí odkaz:
https://doaj.org/article/3f762b2947fa45439b6857349ca801c1
Publikováno v:
Molecules, Vol 29, Iss 2, p 490 (2024)
Extensive research has been dedicated to develop compounds that can target multiple aspects of Alzheimer’s disease (AD) treatment due to a growing understanding of AD’s complex multifaceted nature and various interconnected pathological pathways.
Externí odkaz:
https://doaj.org/article/927fde6128de4a1cb54f6a6234a2ce51
Autor:
Efthalia Angelopoulou, Evangelia Stanitsa, Claire Chrysanthi Karpodini, Anastasia Bougea, Dionysia Kontaxopoulou, Stella Fragkiadaki, Christos Koros, Vasiliki Epameinondas Georgakopoulou, George Fotakopoulos, Yiannis Koutedakis, Christina Piperi, Sokratis G. Papageorgiou
Publikováno v:
Medicina, Vol 59, Iss 8, p 1454 (2023)
Depression represents one of the most common non-motor disorders in Parkinson’s disease (PD) and it has been related to worse life quality, higher levels of disability, and cognitive impairment, thereby majorly affecting not only the patients but a
Externí odkaz:
https://doaj.org/article/7e3f39d61e364f47949e982cb5a7676d
Autor:
Emilio Mateev, Maya Georgieva, Alexandrina Mateeva, Alexander Zlatkov, Shaban Ahmad, Khalid Raza, Vasco Azevedo, Debmalya Barh
Publikováno v:
Molecules, Vol 28, Iss 12, p 4814 (2023)
With the significant growth of patients suffering from neurodegenerative diseases (NDs), novel classes of compounds targeting monoamine oxidase type B (MAO-B) are promptly emerging as distinguished structures for the treatment of the latter. As a pro
Externí odkaz:
https://doaj.org/article/3b390f02030847739d549c581e261e5d
Autor:
A. A. Tappakhov, T. E. Popova, A. I. Vasilev, T. G. Govorova, Yu. I. Khabarova, K. A. Timofeeva, N. A. Schnaider
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 13, Iss 3, Pp 75-81 (2021)
Objective: to assess the predictors and prevalence of adverse drug reactions (ADRs) associated with antiparkinsonian drugs.Materials and methods. 18 clinical studies and randomized controlled trials were included in the analysis. We combined all regi
Externí odkaz:
https://doaj.org/article/8fc38d35a9414e7a8b0a46a15c7ac787
Autor:
N. V. Titova, A. A. Portupeev
Publikováno v:
Медицинский совет, Vol 0, Iss 2, Pp 63-74 (2021)
Treatment of Parkinson’s disease (PD) includes the administration of dopaminergic and occasionally non-dopaminergic drugs, in mono- or in combination therapy. One of the key drug used to treat Parkinson’s disease is levodopa considered a gold sta
Externí odkaz:
https://doaj.org/article/49b469d1208542399d2f19482ab702ca
Autor:
Ahmed H. E. Hassan, Hyeon Jeong Kim, Keontae Park, Yeonwoo Choi, Suyeon Moon, Chae Hyeon Lee, Yeon Ju Kim, Soo Bin Cho, Min Sung Gee, Danbi Lee, Jong-Hyun Park, Jong Kil Lee, Jong Hoon Ryu, Ki Duk Park, Yong Sup Lee
Publikováno v:
Antioxidants, Vol 12, Iss 5, p 1033 (2023)
Oxidative catabolism of monoamine neurotransmitters by monoamine oxidases (MAOs) produces reactive oxygen species (ROS), which contributes to neuronal cells’ death and also lowers monoamine neurotransmitter levels. In addition, acetylcholinesterase
Externí odkaz:
https://doaj.org/article/51c4602921694db4a6786dc3cf8aa3d3